Severe forms of neurocysticercosis: Treatment with albeimdazole
Loading...
External sources
External sources
Date
Advisor
Coadvisor
Graduate program
Undergraduate course
Journal Title
Journal ISSN
Volume Title
Publisher
Type
Article
Access right
Acesso aberto
External sources
External sources
Abstract
Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.
Description
Keywords
Albendazole , Cysticercosis , Dextrochloropheniramine , Ketoprofen , Neurocysticercosis , Severe forms , Treatment , acetazolamide , albendazole , dexchlorpheniramine , ketoprofen , mannitol , adolescent , adult , clinical article , drug efficacy , female , human , male , neurocysticercosis , Adolescent , Adult , Anthelmintics , Brain Diseases , Chlorpheniramine , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Tomography, X-Ray Computed
Language
English
Citation
Arquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996.
